Latest From Biotech Now

2012 Orphan Disease Forum: Addressing Today’s Opportunities and Challenges

disease

If all of the people with rare disease lived in one country, it would be the world’s third most populous country! Through dedicated companies such as the National Organization for Rare Disorders (NORD) and Centric Health Resources, the pressing issue of orphan diseases and its patients are being addressed. A rare disease is defined by any disease affecting fewer than 200,000 Americans. There are nearly 7,000 such diseases affecting over 350 million people worldwide.  Furthermore, Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

2012 MassBioEd Innovative School of the Year – Norton High School

Students

Massachusetts is home to the full ecosystem of life sciences—including our world class academic institutions and medical centers, a vibrant venture capital community, hundreds of biotech companies of all sizes, contract research and manufacturing organizations, and service organizations supporting the industry. It is no wonder then that eleven years ago MassBio established the Massachusetts Biotechnology Foundation to promote biotechnology education and workforce development programs. Each year, the Foundation awards the Innovative School of the Year Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,

Indices, IPOs, and New Drug Approvals – Update April 3rd 2012

Index-March-20121

1. Stock Performance. The Nasdaq Biotech Index (NBI) continued to outperform in March, maintaining its Year-to-Date (YTD) lead of 18% vs. 12% for the S&P 500. Concentrated portfolios holding Amlyin, Regeneron, and Illumina came out even higher. For example, the Amex Biotech Index (BTK) is up 29% this year mainly because it held concentrated positions in these names. Amylin (ALMN) has doubled on the FDA approval for Bydureon and post-approval buy-out rumors. Illumina (ILMN) is up 72% Read More >

Inside BIO Industry Analysis  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Food Crisis Requires “an End to Political Grandstanding”

plant-breeding

Nature Biotechnology published an editorial in their March edition in which they state that averting a global food crisis will require the deconstruction of several hurdles to the deployment of new strategies in plant breeding. Last October, just 12 years after the 6 billionth person was born, the United Nations declared that 7 billion people now inhabit the earth. Of these 7 billion, close to a billion are chronically undernourished and another billion are malnourished. Read More >

Farmer Gene  |  Leave a comment  |  Email This Post
Tags: , , , ,

India Compulsory License: A Times of India Article Says It’s Not Helping the Poor

india-btn

India recently issued a compulsory license on Bayer’s liver and kidney cancer drug (Sorafenib) with the stated goal of providing access to India’s poor. However, the Times of India recently ran the article Cheap generics drugs no panacea for India’s poorest, quickly dispelling this myth: “The compulsory license system might not really work because poor people cannot even afford the discounted price,” said G. Balachandhran, former head of the National Pharmaceutical Pricing Authority (NPPA), India’s drug Read More >

Patently BIOtech  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , ,